Radiation Therapy Plus Thalidomide and Temozolomide in Treating Patients With Newly Diagnosed Brain Metastases

Completed · Phase 2

Conditions studied: Brain and Central Nervous System Tumors, Unspecified Adult Solid Tumor, Protocol Specific

In brief

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Thalidomide may stop the growth of cancer by stopping blood flow to the tumor. Combining whole-brain radiation therapy with thalidomide and temozolomide may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining whole-brain radiation therapy with thalidomide and temozolomide in treating patients who have newly diagnosed brain metastases.

Key facts

Study ID

NCT00049361

Run by

Wake Forest University Health Sciences

Starts

2004-01-01

Expected to finish

2004-12-07

Last updated by the study team

2021-09-09

Who can join

Age: 18 and older, up to 120. Sex: any. Healthy volunteers: not accepted.

Where it is running

• CCOP - Central Illinois — Decatur, Illinois, United States
• CCOP - Southeast Cancer Control Consortium — Goldsboro, North Carolina, United States
• Comprehensive Cancer Center at Wake Forest University — Winston-Salem, North Carolina, United States
• CCOP - Greenville — Greenville, South Carolina, United States
• CCOP - Upstate Carolina — Spartanburg, South Carolina, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.